Biote

Biote EV/Revenue

The EV/Revenue (Enterprise Value to Revenue) of Biote (BTMD) as of Nov 5, 2026 is 0.95. In the previous year, EV/Revenue (Enterprise Value to Revenue) was 0.86 — a change of 11.27% (higher).

EV/Revenue

0.95

YoY

11.27%

Last updated:

EV/Revenue (Enterprise Value to Revenue) of Biote is 2025 0.95 . EV/Revenue (Enterprise Value to Revenue) of Biote was 2024 0.86 . It decreases by 11.27% higher compared to the previous year.

The Biote EV/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/Revenue
Date
EV/Revenue
Jan 1, 2019
1.22 USD
Jan 1, 2020
1.05 USD
Jan 1, 2021
0.77 USD
Jan 1, 2022
0.84 USD
Jan 1, 2023
0.66 USD
Jan 1, 2024
0.86 USD
Jan 1, 2025
0.95 USD
The Biote EV/Revenue history
YEAREV/RevenueYoY
0.95+11.27%
0.86+28.85%
0.66-20.86%
0.84+8.50%
0.77-26.33%
1.05-13.76%
1.22—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biote Stock analysis

What does Biote do? biote Corp. generates revenue through its Biote Method platform, which offers certified practitioners comprehensive tools for hormone optimization. The platform includes education, training, certification, practice management software, inventory management software, and marketing support. Biote also sells a branded line of dietary supplements directly to practitioners and patients. The company's primary customers are Biote-certified practitioners who use the platform to build and manage hormone optimization programs, while the dietary supplements target patients seeking complementary wellness solutions. The Biote Method's proprietary clinical decision support (CDS) system helps physicians personalize patient dosing, enhancing the value proposition for practitioners. By providing end-to-end solutions—from certification to software tools—biote Corp. creates recurring revenue streams through ongoing platform usage and product sales. The company's focus on hormone replacement therapy (HRT) products and practitioner support positions it within the specialized healthcare market segment for bio-identical hormone therapy. biote Corp. differentiates itself through its woman-led structure and comprehensive approach to hormone optimization. The firm's revenue model relies on both service-based offerings for practitioners and direct sales of branded supplements. This dual approach ensures consistent income from certified practitioners who depend on the platform for practice management and from patients purchasing the supplement line as part of their wellness regimen. Biote is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biote stock

EV/Revenue (Enterprise Value to Revenue) of Biote is 0.95 in 2025.

EV/Revenue (Enterprise Value to Revenue) of Biote changed from 0.86 to 0.95, representing a 11.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) Biote since 2006 – with annual values, charts, and detailed analysis.

The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.

To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s Biote with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biote

All Key Metrics — Biote